Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder

Size: px
Start display at page:

Download "Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder"

Transcription

1 Jpn J Clin Oncol 2002;32(1)14 18 Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder Isao Hara, Hideaki Miyake, Shoji Hara, Akinobu Gotoh, Hiroshi Okada, Soichi Arakawa and Sadao Kamidono Department of Urology, Kobe University School of Medicine, Kobe, Japan Received August 8, 2001; accepted October 4, 2001 Objective: To determine whether the timing of radical cystectomy affects the survival of patients with invasive transitional cell carcinoma (TCC) of the bladder. Methods: Between January 1985 and June 2000, 167 patients underwent radical cystectomy in our institution. Among them, 50 patients who did not receive any perioperative therapies, including chemotherapy and radiotherapy, were divided into two groups, viz. 28 patients who underwent radical cystectomy within 3 months after the primary diagnosis of invasive bladder cancer (group A) and 22 who underwent radical cystectomy more than 3 months after the primary diagnosis (group B), and we then compared several clinicopathological factors and the survival between these two groups. Results: No significant difference was observed in the patients clinicopathological characteristics except for age between these two groups. The median follow-up periods for groups A and B were 53 and 48 months, respectively. In groups A and B, an average of 1.2 (range 1 2) and 1.4 (range 1 3) transurethral resections (TURs) of bladder cancer were performed, respectively (p = 0.83). Twenty of 28 patients in group A underwent orthotopic neobladder replacement, whereas only four of 22 underwent neobladder creation (p = 0.001). The recurrence-free, cause-specific and overall survival rates in group A were significantly higher than those in group B (p < 0.05, p <0.05andp < 0.05, respectively). Final pathological analysis revealed that the distributions of pathological stage, tumor grade and lymph node metastasis were similar between groups A and B; however, the incidence of vascular involvement in group B was significantly higher than that in group A (p < 0.05), despite the lack of a significant difference in the incidence of vascular involvement in TUR specimens between these two groups. Conclusions: These findings suggest that radical cystectomy in the early disease process, especially before the occurrence of vascular involvement, may result in the improvement of survival of patients with invasive TCC of the bladder. Key words: invasive bladder cancer timing of radical cystectomy survival INTRODUCTION Radical cystectomy has evolved to be the gold standard treatment for muscle invasive bladder cancer with an overall 5-year disease-free survival rate of 50 70% (1 3). However, muscleinvasive TCC has an aggressive malignant phenotype that has been shown to have a high propensity for disease-recurrence (1 4). In fact, several studies have reported that recurrence develops in up to 50% of patients who are considered as undergoing curative surgery based on the findings of pathological examinations (1 4). Furthermore, to date, there have been no supportive perioperative therapies that significantly improve For reprints and all correspondence: Isao Hara, Department of Urology, Kobe University School of Medicine, Kusunoki-cho, Chuo-ku, Kobe, , Japan the survival of patients with invasive TCC (5 7). These findings suggest that the currently accepted therapeutic strategy for muscle-invasive TCC should be re-evaluated. Recently, several options, which affect the timing of radical cystectomy for invasive TCC, have been reported. For example, continent urinary diversions have been developed and offered to patients undergoing radical cystectomy (8), among which orthotopic neobladder has become the most favored form of urinary diversion, especially since the risk of surgical complications associated with these procedures has decreased with improved operative techniques and additional surgical experience (8,9). However, various problems caused by urinary diversion remain to be elucidated (8,9) and, therefore, the correct timing of cystectomy and the optimal kind of urinary diversion are still difficult challenges for both the urologist and patient. In 2002 Foundation for Promotion of Cancer Research

2 Jpn J Clin Oncol 2002;32(1) 15 Table 1. Patients characteristics Characteristic Group A (n =28) Group B (n =22) p-value Mean age (range) (years) 64.2 (54 76) 72.5 (59 84) <0.01 Gender (male/female) 23/5 19/3 NS Mean follow-up period (range) (months) 53.3 (8 79) 48.8 (8 66) NS Mean interval from diagnosis of invasive disease to cystectomy (range) (months) 1.9 ( ) 3.6 ( ) <0.05 Numbers of TUR (range) 1.2 (1 2) 1.4 (1 3) NS Clinical T stage (%) T2 27 (96) 21 (95) NS T3 1(4) 1(5) T4 0(0) 0(0) Clinical N stage (%) N0 28 (100) 21 (95) NS N1 or more 0(0) 1(5) Grade* (%) G1 0(0) 0(0) NS G2 4(14) 3 (14) G3 24 (86) 19 (86) Multiplicity (%) Single 9(32) 8 (36) NS Multiple 19 (68) 14 (64) Tumor size (%) <2 cm 13 (46) 11 (50) NS 2 cm 15 (54) 11 (50) Vascular involvement* (%) Negative 14 (50) 13 (59) NS Positive 14 (50) 9 (41) Type of urinary diversion Neobladder 20 (71) 4 (18) <0.001 Incontinent urinary diversion 8(29) 18 (82) *Determined based on the findings of initial transurethral resection (TUR). Not significant. addition, several studies have reported the strategies (10 13), including radical transurethral resection (TUR) plus systemic chemotherapy and intra-arterial chemotherapy plus radiation, for invasive disease in an attempt to preserve the bladder, but it is still unclear whether these options result in improved survival. In the present study, we analyzed the relationship between the interval from the diagnosis of invasive bladder cancer to radical cystectomy and survival in a homogeneous contemporary series of patients with adequate follow-up after treatment with radical cystectomy for invasive TCC of the bladder. PATIENTS AND METHODS Between January 1985 and June 2000, 167 patients with invasive TCC of the bladder underwent radical cystectomy, pelvic lymphadenectomy (bilateral iliac and obturator nodes dissection) and urinary diversion for invasive bladder cancer in our institution. Among them, 50 patients who did not receive any perioperative therapies, including chemotherapy and radiotherapy, were divided into two groups, viz. 28 patients who underwent radical cystectomy within 3 months after the primary diagnosis of invasive bladder cancer (group A) and 22 who underwent radical cystectomy more than 3 months after the primary diagnosis (group B). Bladder cancer was diagnosed by transurethral resection. Physical examination, laboratory studies, chest radiography and intravenous pyelogram (IVP) were performed in all patients. Computed tomography (CT), magnetic resonance imaging and/or abdominal ultrasonography were used for clinical staging. All pathological examinations were performed by a single pathologist. The tumor stage and grade were examined

3 16 Timing of radical cystectomy Table 2. Comparison of survival rates according to the 1997 TNM system and the World Health Organization system, respectively. Vascular involvement was defined only when cancer cells were detected in a thin-walled, endothelium-lined space consisting of blood and/or lymph vessels. We directed particular attention toward artefacts due to peritumoral edema and tissue shrinkage for the detection of vascular involvement. In our institution, concomitant urethrectomy was performed in patients with preoperative histologically confirmed bladder cancer of the urethra and/or prostate. When the patient was physiologically able to tolerate a major operation and perform the normal activities of daily life without compromise, it basically depended on the patient s decision whether orthotopic neobladder replacement or incontinent urinary diversion (ureterocutaneostomy or ileal conduit) was selected, except for one case, that is, neobladder was contraindicated only in patients with urethral involvement. The patients were initially seen 2 months after surgery and then every 3 months for 2 years and every 6 months until disease progression or death. Laboratory studies and urinary cytology were performed every 3 months and chest radiography, abdominal and/or pelvic CT and IVP were carried out every 6 months. For those patients who underwent neobladder replacement, neocystoscopy was performed every 12 months. All survival data were analyzed as the cause-specific survival by the Kaplan Meier technique using a log-rank test. The prognostic value for some parameters was determined by multivariate Cox regression models. The level of significance was set at p < RESULTS Group A (year) Survival rate (%) Group B (year) p-value Recurrence-free survival <0.05 Cause-specific survival <0.05 Overall survival <0.05 In this series, 50 patients underwent radical cystectomy and pelvic lymphadenectomy, including simultaneous orthotopic neobladder replacement in 24 patients (ileal neobladder in one patient, ascending colon neobladder in six patients and sigmoid colon neobladder in 17 patients) and incontinent urinary diversionin26patients(ureterocutaneostomyinfourpatients and ileal conduit in 22 patients). We then divided them into two groups according to the timing of radical cystectomy as described above and the comparison between the patients characteristics of these two groups is summarized in Table 1. No significant difference was observed in the gender, the follow-up period, the number of previous TURs of bladder tumors, tumor size, multiplicity, the distribution of clinical T Table 3. Comparison of final pathological examination Pathological T stage (%) Group A (n =28) Group B (n =22) p-value T2 20 (75) 14 (64) NS T3 6(21) 6 (27) T4 1(4) 2(9) Pathological N stage (%) N0 27 (96) 19 (86) NS N1 or more 1(4) 3 (14) Grade* (%) G1 0(0) 0(0) NS G2 5(18) 4 (18) G3 23 (82) 18 (82) Vascular involvement* (%) Negative 15 (54) 6 (27) <0.05 Positive 13 (46) 16 (73) *Determined based on findings of radical cystectomy specimens. Not significant. stage, N stage and tumor grade and the incidence of vascular involvement between these groups, whereas the mean age in group B was significantly higher than that in group A (p < 0.01) and the ratio of patients who underwent neobladder creation in group A was significantly higher than that in group B (p < 0.001). The median follow-up periods for groups A and B were 53 and 48 months, respectively. As shown in Table 2, the recurrence-free, cause-specific and overall survival rates in group A were significantly higher than those in group B (p < 0.05, p < 0.05 and p < 0.05, respectively). During the observation period in the present study, three and 10 patients in groups A and B, respectively, died of cancer metastases, which were initially diagnosed as retroperitoneal lymph node metastasis in six patients, lung metastasis in five and bone metastasis in two. Final pathological examinations revealed that no significant difference was observed in the distribution of the T stage, N stage and tumor grade, whereas the incidence of vascular involvement in group B was significantly higher than that in group A (p < 0.05) (Table 3). In addition, the mean interval and range from the diagnosis of invasive disease to radical cystectomy inpatients with and without subsequent vascular involvement were 1.7 ( ) and 3.9 ( ) months, respectively (p < 0.01). However, a Cox multivariate regression analysis revealed that only the pathological stage and nodal involvement were independent prognostic predictors, irrespective of gender, age, tumor grade, vascular involvement, tumor size, multiplicity, type of urinary diversion and the interval from the diagnosis of invasive bladder cancer to radical cystectomy (data not shown).

4 Jpn J Clin Oncol 2002;32(1) 17 DISCUSSION The finding that cancer cells have broken through the basement membrane and into the muscular propria reflects a different malignant potential with a propensity for metastases; therefore, muscle-invasive bladder cancer is the usual indication for radical cystectomy and pelvic lymphadenectomy. Despite recent therapeutic advances, such as surgical techniques and perioperative cytotoxic chemotherapy, the survival of invasive bladder cancer patients with pathological risk factors, including advanced stage, lymph node metastasis and vascular involvement, after radical cystectomy remains unsatisfactory (1 5). Furthermore, several therapeutic options for invasive diseases, which affect the timing of radical cystectomy, have become available (10 13). Recently, Sanchez- Ortiz et al. reported that a delay of radical cystectomy of longer than 3 months is associated with advanced pathological stage and decreased survival (14). These findings prompted us to re-evaluate the current therapeutic strategy for invasive TCC of the bladder and here we performed a retrospective analysis in a homogeneous contemporary series of patients who underwent radical cystectomy but not any perioperative therapies for invasive bladder cancer, focusing on the significance of the interval from the diagnosis of invasive disease to radical cystectomy. In this series, the patients characteristics between groups A and B were similar except for age and the ratio of patients with orthotopic neobladder. There were some reasons for these differences in age and the type of urinary diversions between these groups. For example, as part of the informed consent, although age alone was not a contraindication, older patients must be made aware that they may have a more frequent postoperative incidence of postoperative complications, such as nocturnal incontinence, than younger men. The reluctance of elderly patients to undergo radical surgery may also be reflected in this difference. However, because of the similar characters in the remaining factors, this difference may not interfere with the objectives of the present study. The timing of the treatment of bladder cancer is extremely important, since ~20% of new cases are invasive disease and an additional 10% of superficial diseases subsequently progress (15). In this series, no significant difference was observed in the average number of previous TURs between groups A and B, while the prognosis of patients with group A was significantly better than that in group B, suggesting that a delay in performing radical cystectomy could be closely associated with the poorer survival in patients with invasive bladder cancer. In fact, a final pathological examination revealed a higher incidence of vascular involvement in group B than group A, despite the lack of a significant difference in the incidence of vascular involvement in the specimens obtained by TUR. These findings may suggest that vascular involvement frequently occurred during the longer interval from the diagnosis to radical surgery in group B compared with group A, resulting in the poorer survival. Various types of urinary diversion have recently been developed and recent advances in this area provide patients with an improved quality of life (16,17). However, various problems caused by urinary diversion remain to be elucidated, such as metabolic acidosis, urolithiasis, enuresis and impaired body image (8,16), and, therefore, the correct timing of cystectomy and the optimal kind of urinary diversion have been common dilemmas for both the urologist and patient. Recently, some studies have indicated that the option of orthotopic neobladder may influence the decision in favor of earlier cystectomy (9,18,19). In the current series, patients who selected orthotopic neobladder replacement as their urinary diversion tended to receive radical cystectomy earlier than those who selected incontinent urinary diversion. These findings suggest that the orthotopic bladder replacement may decrease the reluctance to perform radical cystectomy early in the disease process. In conclusion, the present findings suggest that radical cystectomy in the early disease process, especially before the occurrence of vascular involvement, may result in the improvement of the survival of patients with invasive TCC of the bladder. We therefore recommend performing radical cystectomy as early as possible after the primary diagnosis of invasive bladder cancer. References 1. Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. JUrol 1999;161: Slaton JW, Swanson DA, Grossman HB, Dinney, CP. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. JUrol1999;162: Hara S, Miyake H, Fujisawa M, Okada H, Arakawa S, Kamidono S, et al. Prognostic variables in patients who have undergone radical cystectomy for transitional cell carcinoma of the bladder. Jpn J Clin Oncol 2001;31: Ennis RD, Petrylak DP, Singh P, Bagiella E, O Toole KM, Benson MC, et al. The effect of cystectomy and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer. JUrol2000;163: Lerner SP, Skinner E, Skinner DG. Radical cystectomy in regionally advanced bladder cancer. Urol Clin N Am 1992;19: Gohji K, Sugino M, Arakawa S, Matsumoto O, Kamidono S, Fujii A, et al. Preoperative adjuvant therapy for urinary bladder cancer. Nippon Hinyoukika Gakkai Zasshi 1990;81: (in Japanese). 7. Miyake H, Gohji K, Hara I, Eto H, Yamanaka K, Arakawa S, et al. Long-term results of neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for locally invasive transitional cell carcinoma of the urothelium. Int J Clin Oncol 1999;4: Turner WH, Bitton A, Studer UE. Reconstruction of the urinary tract after radical cystectomy: the case for continent urinary diversion. Urology 1997;49: Hautmann RE, Paiss T. Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy? J Urol 1998;159: Thomas DJ, Roberts JT, Hall RR, Reading J. Radical transurethral resection and chemotherapy in the treatment of muscle-invasive bladder cancer: a long-term follow-up. BJU Int 1999;83: Feneley MR, Mellon JK. Management dilemmas in bladder cancer: radical TUR +/ systemic chemotherapy in the treatment of muscle-invasive bladder cancer. Semin Urol Oncol 2000;18: Miyanaga N, Akaza H, Okumura T, Sekido N, Kawai K, Shimazui T, et al. A bladder preservation regimen using intra-arterial chemotherapy and

5 18 Timing of radical cystectomy radiotherapy for invasive bladder cancer: a prospective study. Int J Urol 2000;7: KageyamaY,OkadaY,AraiG,HyochiN,SuzukiM,MasudaH,etal. Preoperative concurrent chemoradiotherapy against muscle-invasive bladder cancer: results of partial cystectomy in elderly or high-risk patients. Jpn J Clin Oncol 2000;30: Sanchez-Ortiz F, van Aradalen KN, Wein AJ, Markowicz SB, Huang, WC. A prolonged interval between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder cancer. JUrol 2000;165(Suppl): Newling D. Preventing recurrence and progression in superficial bladder cancer. Curr Opin Urol 1996; 6: Frazier HA, Robertson JE, Paulson DF. Complications of radical cystectomy and urinary diversion: a retrospective review of 675 cases in 2 decades. JUrol1992;148: Bjerre BD, Johansen C, Steven K. Health-related quality of life after cystectomy: bladder substitution compared with ileal conduit diversion. A questionnaire survey. Br J Urol 1995;158: Skinner DG, Boyd SD, Lieskovsky G, Bennet C, Hopwood B. Lower urinary tract reconstruction following cystectomy: experience and results in 126 patients using the Kock ileal reservoir with bilateral ureteroileal urethrostomy. JUrol1991;146: Hautmann RE, Miller K, Steiner U, Wenderoth U. The ileal neobladder: 6 years of experience with more than 200 patients. JUrol1993;150:40 5.

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu

More information

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER 10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg

More information

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in

More information

Influence of stage discrepancy on outcome in. in patients treated with radical cystectomy.

Influence of stage discrepancy on outcome in. in patients treated with radical cystectomy. Tumori, 96: 699-703, 2010 Influence of stage discrepancy on outcome in patients treated with radical cystectomy Ja Hyeon Ku 1, Kyung Chul Moon 2, Cheol Kwak 1, and Hyeon Hoe Kim 1 1 Department of Urology,

More information

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction

More information

Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience

Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura

More information

Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors

Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau

More information

A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density

A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density Clinical Urology TCC of the Bladder and Lymph Node Density International Braz J Urol Vol. 32 (5): 536-549, September - October, 2006 A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma

More information

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research   ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Outcome of Open Radical Cystectomy and Ileal Conduit: A Single Center Experience Mahesh Kalloli

More information

Evaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population

Evaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after

More information

Radical Cystectomy Often Too Late? Yes, But...

Radical Cystectomy Often Too Late? Yes, But... european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer

More information

Index. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,

More information

Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy

Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy Japanese Journal of Clinical Oncology, 2015, 45(10) 963 967 doi: 10.1093/jjco/hyv098 Advance Access Publication Date: 29 July 2015 Original Article Original Article Impact of adjuvant chemotherapy on patients

More information

REVIEW. Patterns of recurrence of bladder carcinoma following radical cystectomy

REVIEW. Patterns of recurrence of bladder carcinoma following radical cystectomy Cancer Imaging (2003) 3, 96 100 DOI: 10.1102/1470-7330.2003.0009 CI REVIEW Patterns of recurrence of bladder carcinoma following radical cystectomy D M Koh and J E Husband Academic Department of Radiology,

More information

Eiji Kikuchi, Yutaka Horiguchi, Jun Nakashima, Takashi Ohigashi, Mototsugu Oya, Ken Nakagawa, Akira Miyajima and Masaru Murai

Eiji Kikuchi, Yutaka Horiguchi, Jun Nakashima, Takashi Ohigashi, Mototsugu Oya, Ken Nakagawa, Akira Miyajima and Masaru Murai Assessment of Long-Term Quality of Life Using the FACT-BL Questionnaire in Patients with an Ileal Conduit, Continent Reservoir, or Orthotopic Neobladder Eiji Kikuchi, Yutaka Horiguchi, Jun Nakashima, Takashi

More information

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction

More information

Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer

Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer The new england journal of medicine original article Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer H. Barton Grossman, M.D., Ronald B. Natale,

More information

YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI KADONO, HIROYUKI KONAKA, ATSUSHI MIZOKAMI and MIKIO NAMIKI

YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI KADONO, HIROYUKI KONAKA, ATSUSHI MIZOKAMI and MIKIO NAMIKI Retrospective Analysis of the Efficacy of Two Cycles of M-VAC Neoadjuvant Chemotherapy Followed by Radical Cystectomy for Muscle-invasive Bladder Cancer YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI

More information

Radical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients

Radical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients Original Article : oncologic outcome in 271 Chinese patients Zhi-Ling Zhang, Pei Dong, Yong-Hong Li, Zhuo-Wei Liu, Kai Yao, Hui Han, Zi-Ke Qin and Fang-Jian Zhou Abstract Few large scale studies have reported

More information

UROTHELIAL CELL CANCER

UROTHELIAL CELL CANCER UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute

More information

Organ-sparing treatment of invasive transitional cell bladder carcinoma

Organ-sparing treatment of invasive transitional cell bladder carcinoma Journal of BUON 7: 241-245, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Organ-sparing treatment of invasive transitional cell bladder carcinoma C. Damyanov, B. Tsingilev,

More information

INVASIVE BLADDER CANCER

INVASIVE BLADDER CANCER INVASIVE BLADDER CANCER - Aspects on staging and prognosis Liedberg, Fredrik 2006 Link to publication Citation for published version (APA): Liedberg, F. (2006). INVASIVE BLADDER CANCER - Aspects on staging

More information

Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience

Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer

More information

Intussusception of the bladder neck does not promote early restoration to urinary continence after non-nervesparing radical retropubi c prostatectomy

Intussusception of the bladder neck does not promote early restoration to urinary continence after non-nervesparing radical retropubi c prostatectomy Blackwell Science, LtdOxford, UKIJUInternational Journal of Urology0919-81722004 Blackwell Publishing Asia Pty LtdMarch 2004123275279Original ArticleIntussusception of the bladder neck and early continencei

More information

Best Papers. F. Fusco

Best Papers. F. Fusco Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical

More information

Bladder replacement in men and women: when and when not? Outline. Continent Diversion History

Bladder replacement in men and women: when and when not? Outline. Continent Diversion History 1 Bladder replacement in men and women: when and when not? Eila C. Skinner, MD Professor of Clinical Urology Keck USC School of Medicine Outline 1) Selection criteria for orthotopic diversion: Tumor-related

More information

When to Integrate Surgery for Metatstatic Urothelial Cancers

When to Integrate Surgery for Metatstatic Urothelial Cancers When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male

More information

Urethral Carcinoma Recurrence in Ileal Orthotopic Neobladder: Urethrectomy and Conversion in a Continent Pouch with Abdominal Stoma

Urethral Carcinoma Recurrence in Ileal Orthotopic Neobladder: Urethrectomy and Conversion in a Continent Pouch with Abdominal Stoma Case Report Urol Int 1999;62:213 216 Received: June 19, 1998 Accepted after revision: March 8, 1999 Urethral Carcinoma Recurrence in Ileal Orthotopic Neobladder: Urethrectomy and Conversion in a Continent

More information

Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity

Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:

More information

Bladder Cancer Guidelines

Bladder Cancer Guidelines Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder

More information

Disease Speci c Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy

Disease Speci c Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy European Urology European Urology 41 2002) 440±448 Disease Speci c Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy JuÈrgen E. Gschwend a,b,*, Philipp Dahm c, WilliamR.

More information

Multiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy

Multiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy Brazilian Journal of Medical and Biological Research (2007) 40: 979-984 Predictive factors after radical cystectomy ISSN 0100-879X 979 Multiple factor analysis of metachronous upper urinary tract transitional

More information

Partial Cystectomy for Invasive Bladder Cancer

Partial Cystectomy for Invasive Bladder Cancer European Urology Supplements European Urology Supplements 4 (2005) 67 71 Partial Cystectomy for Invasive Bladder Cancer Gerald H. Mickisch* Center of Operative Urology Bremen, Academic Hospital Bremen

More information

TCC recurrence within the upper tract urothelium following

TCC recurrence within the upper tract urothelium following Upper Tract Urothelial Recurrence Following Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: An Analysis of 1,069 Patients With 10-Year Followup Kristin M. Sanderson,* Jie Cai, Gustavo

More information

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching

More information

BJUI. 35% had lymph node involvement at radical cystectomy or subsequent recurrence within the dissection template.

BJUI. 35% had lymph node involvement at radical cystectomy or subsequent recurrence within the dissection template. 2010 THE AUTHORS; 2010 Urological Oncology LYMPH NODE STATUS IN PT0 BLADDER CANCER KAAG ET AL. BJUI Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical

More information

Transitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as a Spinal Cord Compression

Transitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as a Spinal Cord Compression Case Study TheScientificWorldJOURNAL (2008) 8, 223 227 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2008.43 Transitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as

More information

Lymphadenectomy with Cystectomy: Is It Necessary

Lymphadenectomy with Cystectomy: Is It Necessary European Urology European Urology 46 (2004) 457 461 Lymphadenectomy with Cystectomy: Is It Necessary and What Is Its Extent? Mohamed A. Ghoneim *, Hassan Abol-Enein Urology & Nephrology Center, Gomhouria

More information

Invasive Bladder Transitional Cell Carcinoma OBJECTIVES

Invasive Bladder Transitional Cell Carcinoma OBJECTIVES Invasive Bladder Transitional Cell Carcinoma UBC Urology Grand Rounds 7 September 2005 John Morrell R5 OBJECTIVES Review role of lymphadenectomy Review role of chemotherapy Review results of bimodal bladder

More information

AUA Guidelines for Invasive Bladder Cancer: What s New?

AUA Guidelines for Invasive Bladder Cancer: What s New? AUA Guidelines for Invasive Bladder Cancer: What s New? Michael S. Cookson, MD, MMHC Professor and Chairman Department of Urology, University of Oklahoma History 1999: AUA guidelines Panel Non-muscle invasive

More information

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA

More information

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell

More information

Hydronephrosis as a Prognostic Marker in Bladder Cancer in a Cystectomy-Only Series

Hydronephrosis as a Prognostic Marker in Bladder Cancer in a Cystectomy-Only Series european urology 51 (2007) 690 698 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Hydronephrosis as a Prognostic Marker in Bladder Cancer in a Cystectomy-Only

More information

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma

More information

Bone Metastases in Muscle-Invasive Bladder Cancer

Bone Metastases in Muscle-Invasive Bladder Cancer Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer

More information

Case 1. Receives induction BCG weekly x 6 without significant toxicity Next step should be:

Case 1. Receives induction BCG weekly x 6 without significant toxicity Next step should be: Case 1 89 year old male with initial occurrence of gross hematuria Office flexible cystoscopy shows two papillary tumors with some surface necrosis Complete TURBT into muscle Florescence cysto shows two

More information

Impact of invasive bladder cancer and orthotopic urinary diversion on general health-related quality of life: An SF-36 survey

Impact of invasive bladder cancer and orthotopic urinary diversion on general health-related quality of life: An SF-36 survey 758 Impact of invasive bladder cancer and orthotopic urinary diversion on general health-related quality of life: An SF-36 survey MINGYING YANG 1,2*, HAIFENG WANG 2*, JIANSONG WANG 2 and MINGHUI RUAN 1

More information

Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49

Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49 OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection

More information

Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder

Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder Safini et al. 31 case Series report peer Reviewed open OPEN ACCESS Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder Fatima Safini, Hassan Jouhadi, Meriem Elbachiri,

More information

GUIDELINES ON PROSTATE CANCER

GUIDELINES ON PROSTATE CANCER 10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal

More information

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Jeffrey M. Holzbeierlein, MD, FACS John W Weigel Professor & Chair Director of Urologic Oncology University of Kansas

More information

BLADDER CANCER: PATIENT INFORMATION

BLADDER CANCER: PATIENT INFORMATION BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,

More information

Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience

Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,

More information

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy

Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo

More information

The right middle lobe is the smallest lobe in the lung, and

The right middle lobe is the smallest lobe in the lung, and ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,

More information

Conclusions. Keywords

Conclusions. Keywords Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy Pascal Zehnder*, Urs E. Studer,

More information

Bladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer

Bladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer Bladder-preserving therapy is a safe and effective alternative to cystectomy for carefully selected patients with bladder cancer. Michael Mahany. Trumpeter Swans on Byer s Lake. Photograph. Denali National

More information

Upper urinary tract urothelial carcinomas (UTUC)

Upper urinary tract urothelial carcinomas (UTUC) Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida

More information

A Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis

A Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'

More information

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer bs_bs_banner Asia-Pacific Journal of Clinical Oncology 2013; 9: 310 317 doi: 10.1111/ajco.12017 ORIGINAL ARTICLE Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for

More information

Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder

Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder Annals of Oncology : -5. 999. 999 Klimer Academic Publishers. Printed in the Netherlands. Original article Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma

More information

Glossary of Terms Primary Urethral Cancer

Glossary of Terms Primary Urethral Cancer Patient Information English Glossary of Terms Primary Urethral Cancer Advanced cancer A tumour that grows into deeper layers of tissue, adjacent organs, or surrounding muscles. Anaesthesia (general, spinal,

More information

Impact of Histopathological Variant on the Outcome of Patients Treated by Radical Cystectomy

Impact of Histopathological Variant on the Outcome of Patients Treated by Radical Cystectomy www.kjurology.org http://dx.doi.org/./kju... Original Article Urological Oncology http://crossmark.crossref.org/dialog/?doi=./kju...&domain=pdf&date_stamp= Impact of Histopathological Variant on the Outcome

More information

Early radical cystectomy in NMIBC Marko Babjuk

Early radical cystectomy in NMIBC Marko Babjuk Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,

More information

Information for Patients. Bladder Cancer. English

Information for Patients. Bladder Cancer. English Information for Patients Bladder Cancer English Table of contents What is the function of the bladder?... 3 What is bladder cancer?... 3 What causes bladder cancer?... 3 Stages of the disease... 3 Risk

More information

Dr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate

Dr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate Dr. Tareq Salah Ahmed,MD,ESMO Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate 1 st Assiut Urology department conference,marsa Alam 3 rd February 2015 Bladder cancer

More information

Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital

Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.

More information

Chapter 8 Adenocarcinoma

Chapter 8 Adenocarcinoma Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted

More information

Role and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017

Role and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Role and extension of lymph node dissection in kidney, bladder and prostate cancer Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Bladder Cancer LN dissection in Bladder cancer 25% of patients

More information

Lung cancer is a major cause of cancer deaths worldwide.

Lung cancer is a major cause of cancer deaths worldwide. ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,

More information

Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients

Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients Yonago Acta medica 2012;55:57 61 Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients Hiroaki Saito, Seigo Takaya, Yoji Fukumoto, Tomohiro Osaki, Shigeru Tatebe and Masahide

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology

More information

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic

More information

Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature

Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature ISPUB.COM The Internet Journal of Urology Volume 7 Number 1 Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature T Hsieh, J Aragon-Ching, J Saia, T Sotelo Citation T

More information

Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases

Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation

More information

URINARY DIVERSIONS. Susan Hilton, MD and Nicholas Papanicolaou, MD Co-Chiefs, CT Section Hospital of the University of Pennsylvania

URINARY DIVERSIONS. Susan Hilton, MD and Nicholas Papanicolaou, MD Co-Chiefs, CT Section Hospital of the University of Pennsylvania URINARY DIVERSIONS Susan Hilton, MD and Nicholas Papanicolaou, MD Co-Chiefs, CT Section Hospital of the University of Pennsylvania Neither of us has any financial relationships with commercial interests

More information

Sexuality Preserving Cystectomy and Neobladder (SPCN): Functional Results of a Neobladder Anastomosed to the Prostate

Sexuality Preserving Cystectomy and Neobladder (SPCN): Functional Results of a Neobladder Anastomosed to the Prostate European Urology European Urology 43 (2003) 646 650 Sexuality Preserving Cystectomy and Neobladder (SPCN): Functional Results of a Neobladder Anastomosed to the Prostate W. Meinhardt *, S. Horenblas Department

More information

Open Radical Cystectomy Tips and Tricks in Males and Females

Open Radical Cystectomy Tips and Tricks in Males and Females Open Radical Cystectomy Tips and Tricks in Males and Females Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine

More information

Bladder-Sparing Treatment of Invasive Bladder Cancer

Bladder-Sparing Treatment of Invasive Bladder Cancer Several alternatives to radical cystectomy for muscle-invasive bladder cancer have been studied. None, however, are reliably superior to operative treatment. Sidi Bou Said,Tunisia, 1999. Courtesy of J.

More information

RITE Thermochemotherapy in the treatment of BCG refractory NMIBC

RITE Thermochemotherapy in the treatment of BCG refractory NMIBC RITE Thermochemotherapy in the treatment of BCG refractory NMIBC Ben Ayres Consultant Urological Surgeon St George s Hospital London 1 Financial and Other Disclosures Off-label use of drugs, devices, or

More information

Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer

Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer Original Article Japanese Journal of Clinical Oncology Advance Access published July 10, 2012 Jpn J Clin Oncol 2012 doi:10.1093/jjco/hys105 Analysis of Intravesical Recurrence After Bladder-preserving

More information

Delay in the Surgical Treatment of Bladder Cancer and Survival: Systematic Review of the Literature

Delay in the Surgical Treatment of Bladder Cancer and Survival: Systematic Review of the Literature european urology 50 (2006) 1176 1182 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Bladder Cancer Delay in the Surgical Treatment of Bladder Cancer and Survival: Systematic

More information

Efficacy of Bladder-Preserving Therapy for Patients with T3b, T4a, and T4b Transitional Cell Carcinoma of the Bladder

Efficacy of Bladder-Preserving Therapy for Patients with T3b, T4a, and T4b Transitional Cell Carcinoma of the Bladder www.kjurology.org DOI:10.4111/kju.2010.51.8.525 Urological Oncology Efficacy of Bladder-Preserving Therapy for Patients with T3b, T4a, and T4b Transitional Cell Carcinoma of the Bladder Jaewoo Cheon, Hyunchul

More information

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group

More information

Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival

Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS

More information

Information for Patients. Primary urethral cancer. English

Information for Patients. Primary urethral cancer. English Information for Patients Primary urethral cancer English Table of contents What is primary urethral cancer?... 3 Risk factors... 3 Symptoms... 4 Diagnosis... 4 Clinical examination... 4 Urinary cytology...

More information

Trimodality Therapy for Muscle Invasive Bladder Cancer

Trimodality Therapy for Muscle Invasive Bladder Cancer Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,

More information

Oral Communications & Posters

Oral Communications & Posters Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica

More information

EAU MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

EAU MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER EAU MUSLE-INVASIVE AND METASTATI LADDER ANER (Limited text update March 2016) J.A. Witjes (hair), E. ompérat, N.. owan, M. De Santis, G. Gakis, N. James, T. Lebret, A.G. van der Heijden, M.J. Ribal Guidelines

More information

Comparison of Three Types of Continent Urinary Diversions in a Single Center

Comparison of Three Types of Continent Urinary Diversions in a Single Center Article TheScientificWorldJOURNAL (2004) 4 (S1), 135 141 ISSN 1537-744X; DOI 10.1100/tsw.2004.59 Comparison of Three Types of Continent Urinary Diversions in a Single Center Cengiz Girgin, M.D., Akif Sezer,

More information

Body Image Following Radical Cystectomy and Ileal Neobladder or Conduit in Korean Patients

Body Image Following Radical Cystectomy and Ileal Neobladder or Conduit in Korean Patients www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.3.161 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.3.161&domain=pdf&date_stamp=2014-03-17

More information

Chemotherapy Treatment Algorithms for Urology Cancer

Chemotherapy Treatment Algorithms for Urology Cancer Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional

More information

Cystectomies and bladder preservation: What you need to know

Cystectomies and bladder preservation: What you need to know Cystectomies and bladder preservation: What you need to know Robin Morash RN, BNSc, MHS Bladder Cancer Canada November 21, 2018 Presentation goals Review the options for treatment of muscle-invasive bladder

More information

Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy

Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Mitsui Memorial Hospital Department of Breast and Endocine surgery Daisuke Ota No financial support

More information

Recovery of sexual function after radical cystectomy with orthotopic neobladder

Recovery of sexual function after radical cystectomy with orthotopic neobladder Recovery of sexual function after radical cystectomy with orthotopic neobladder C. Gingu, V. Olaru, A. Dick, C. Baston, M. Crăsneanu, C. Surcel, S. Voinea, Liliana Domnişor, I. Sinescu Center of Urological

More information

Citation International journal of urology (2. Right which has been published in final f

Citation International journal of urology (2.  Right which has been published in final f Title Novel constant-pressure irrigation of renal pelvic tumors after ipsila Nakamura, Kenji; Terada, Naoki; Sug Author(s) Toshinori; Matsui, Yoshiyuki; Imamu Kazutoshi; Kamba, Tomomi; Yoshimura Citation

More information